Rhythm Pharmaceuticals, Inc. Common Stock RYTM
Key Stats
- Today's Range
- $84.88 – $87.10
- 50-Day Range
- $74.50 – $99.00
- 52-Week Range
- $55.31 – $122.20
- Volume
- 489K shs
- Average Volume
- 687K shs
- Market Cap
- $5.89 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 47.95
- Price / Sales
- 27.14
Short Interest
- Short Interest
- 1.12%
- Days to Cover
- 5.67
Financials (TTM)
- Revenue
- $217.16 million
- Net Income
- $-202,680,000
- Net Margin
- -93.33%
- Return on Equity
- -164.91%
- Debt-to-Equity
- —
About Rhythm Pharmaceuticals, Inc. Common Stock
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Related Stocks
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.